lymphoma
FDA Approves Monjuvi for Relapsed or Refractory Follicular Lymphoma
The FDA approved Monjuvi with lenalidomide and rituximab for adults with relapsed or refractory follicular ...
JUNE 20, 2025
Supportive Care and Other Tools for Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In patients who received prior CLL/SLL-directed therapy but require additional treatment, decisions may depend on ...
APRIL 29, 2025
Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CLL is a lymphoproliferative disorder characterized by the accumulation of circulating mature B cells that are ...
MARCH 20, 2024
FDA Requires Boxed Warning of Secondary Malignancies for CAR-T Therapies
The FDA has called for a classwide boxed warning on all commercial CAR T-cell therapies after an investigation into ...
FEBRUARY 6, 2024
Next-Generation Sequencing Helps Risk-Stratify Pediatric Leukemia Patients
By accurately assessing minimal residual disease status, next-generation sequencing is showing promise for more ...
JANUARY 26, 2022
Glucardipase Keeps CNS Lymphoma Rx on Track
Anew outpatient treatment regimen allowed patients with CNS lymphoma to continue infusions during the height of the ...
MAY 24, 2021
Xpovio Approved to Treat Relapsed or Refractory DLBCL
The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) for the treatment of adult patients with ...
JUNE 23, 2020
